Rafał Wyderka

Dr. Rafał Wyderka


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RWRafał Wyderka
Rafał Wyderka
ŁOŁukasz Osuch
Łukasz Osuch
BOBogusława Ołpińska
Bogusława Ołpińska
MŁMaria Łoboz-Rudnicka
Maria Łoboz-Rudnicka
DDDorota Diakowska
Dorota Diakowska
JJJoanna Jaroch
Joanna Jaroch
The apelin–ELABELA–APJ axis, collectively known as the apelinergic system, has emerged as a key regulator of cardiovascular homeostasis. Acting through G-protein-coupled mechanisms, it modulates vascular tone, cardiac contractility, angiogenesis, fluid balance, and metabolism. Growing evidence indicates that dysregulation of apelinergic signaling contributes to the development and progression of atherosclerosis, hypertension, and heart failure. Experimental studies demonstrate cardioprotective actions of apelin and ELABELA, including anti-fibrotic, anti-inflammatory, vasodilatory, and pro-angiogenic effects, whereas some findings suggest context-dependent pro-atherogenic or vasoconstrictive roles. Clinical data show that circulating apelinergic peptides vary across cardiovascular conditions, being upregulated in acute coronary syndromes and diminished in chronic ischemic or hypertensive disease. In heart failure, early compensatory activation is followed by progressive depletion, and low ELABELA levels correlate with disease severity. Moreover, the apelinergic system may exert anti-arrhythmic effects through modulation of myocardial electrophysiology and structural remodeling. Novel synthetic APJ agonists and stabilized peptide analogs show promising preclinical efficacy in reducing cardiac remodeling, improving contractility, and lowering blood pressure. Altogether, the apelinergic pathway represents a multifaceted modulator and a promising therapeutic target in cardiovascular medicine, warranting further translational studies to elucidate its diagnostic and treatment potential.

26 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DDDorota Diakowska
Dorota Diakowska
RWRafał Wyderka
Rafał Wyderka
MKMalgorzata Krzystek-Korpacka
Malgorzata Krzystek-Korpacka
ŁOŁukasz Osuch
Łukasz Osuch
ALAnna Leśków
Anna Leśków
JJJoanna Jaroch
Joanna Jaroch
The effects of the apelinergic system components apelin (AP) and elabela (ELA) in the regulation of human cardiovascular homeostasis, and data concerning the relationship between ELA and AP and coronary artery disease (CAD) are yet unknown. The aim of the study was the evaluation of AP, ELA and APJ-receptor levels in the plasma of patients with chronic coronary syndromes (CCS) and acute coronary syndromes (ACS). The study group consisted of 114 patients with CAD and 33 healthy controls. Patients were divided into two groups: with CCS (n = 30) and ACS (n = 84). Routine laboratory tests and plasma ELA, AP-17, AP-13 and APJ receptor levels were measured. Echocardiographic data were analyzed in all patients. Levels of AP-17 and ELA were significantly lower in CCS than in healthy controls and ACS patients. We demonstrated significant increase of levels of plasma apelinergic system peptides, especially ELA and AP-17 in ACS patients compared with healthy controls and CCS, suggestive of compensating up-regulation mechanisms. There is a relationship between circulating ELA and AP-17 levels and classical, biochemical markers of ischemia and left ventricular ejection faction as well.

5 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
RWRadosław Wontor
Radosław Wontor
MLMagdalena Lisiak
Magdalena Lisiak
MŁMaria Łoboz-Rudnicka
Maria Łoboz-Rudnicka
BOBogusława Ołpińska
Bogusława Ołpińska
RWRafał Wyderka
Rafał Wyderka
JJJoanna Jaroch
Joanna Jaroch
Background/Objectives: The ageing population has heightened interest in the prognostic role of geriatric conditions, notably frailty syndrome (FS) and cognitive impairment (CI). Evidence indicates a significant link between cardiovascular disease, FS, and CI. However, limited research has explored the impact of impaired functional and cognitive performance on outcomes in acute coronary syndrome (ACS) patients. This study aimed to evaluate the effect of coexisting FS and CI (FSxCI) on early and 6-month complications in older adults with ACS. Methods: This study included 196 ACS patients (119 men) aged 65 and over (mean = 74.7 years), with 90.8% undergoing invasive treatment (PCI in 81.6%, CABG in 9.2%). FS and CI were assessed on the third hospital day using the Tilburg Frailty Indicator (TFI) and Mini Mental State Examination (MMSE). Early (in-hospital) complications included major bleeding, ventricular arrhythmia (VT), conduction disturbances, cardiac arrest, stent thrombosis, acute heart failure (Killip–Kimball class III/IV), stroke, prolonged stay, and in-hospital death. Six-month follow-up recorded major adverse cardiovascular and cerebrovascular events (MACCEs). Results: Patients with FSxCI (n = 107, 54.6%) were older and had higher hypertension prevalence and lower nicotine dependence. FSxCI patients faced over twice the risk of prolonged hospital stays (OR 2.39; p = 0.01) and nearly three times the risk of early complications (OR 2.73; p < 0.001). At 6 months, FSxCI tripled the risk of MACCEs (OR 2.8; p = 0.007). Kaplan–Meier analysis confirmed a worse 6-month prognosis for FSxCI patients. Conclusions: Elderly patients with ACS and concomitant FSxCI had significantly higher rates of early (in-hospital) and 6-month complications. FSxCI was associated with a worse 6-month prognosis. This highlights its significance for clinical decision-making, as identifying FSxCI in ACS patients can help prioritize high-risk individuals for tailored interventions, optimize resource allocation, and improve outcomes.

10 December 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RWRafał Wyderka
Rafał Wyderka
DDDorota Diakowska
Dorota Diakowska
MŁMaria Łoboz-Rudnicka
Maria Łoboz-Rudnicka
JMJakub Mercik
Jakub Mercik
MBMichał Borger
Michał Borger
JJJoanna Jaroch
Joanna Jaroch
Background: There is a growing body of evidence for an important role of the apelinergic system in the modulation of cardiovascular homeostasis. The aim of our study was to (1) examine the relationship between apelin serum concentration at index myocardial infarction (MI) and atrioventricular conduction disorders (AVCDs) at 12-month follow-up, and (2) investigate the association between initial apelin concentration and the novel marker of post-MI scar (Q/QRS ratio) at follow-up. Methods: In 84 patients with MI with complete revascularization, apelin peptide serum concentrations for apelin-13, apelin-17, elabela (ELA) and apelin receptor (APJ) were measured on day one of hospitalization; at 12-month follow-up, 54 of them underwent thorough examination that included 12-lead electrocardiography (ECG), Holter ECG monitoring and echocardiography. Results: The mean age was 58.9 years. At 12-month follow-up, AVCDs were diagnosed in 21.4% of subjects, with AV first-degree block in 16.7% and sinoatrial arrest in 3.7%. ELA serum concentration at index MI correlated positively with the occurrence of AVCD (p = 0.003) and heart rate (p = 0.005) at 12-month follow-up. The apelin-13 serum concentration at index MI correlated negatively with the Q/QRS ratio. Conclusions: The apelin peptide concentration during an acute phase of MI impacts the development of AVCD and the value of Q/QRS ratio in MI survivors.

28 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MKMateusz Kuśmierz
Mateusz Kuśmierz
JMJakub Mercik
Jakub Mercik
MŚMarek Śledziona
Marek Śledziona
BBBarbara Brzezińska
Barbara Brzezińska
MŁMaria Łoboz-Rudnicka
Maria Łoboz-Rudnicka
JJJoanna Jaroch
Joanna Jaroch
Background: In the population of patients with ischemic cardiomyopathy (IC) and reduced left ventricular ejection fraction, the benefits of prophylactic implantable cardioverter-defibrillator (ICD) therapy are not uniform. Identifying predictors of ventricular arrhythmias to estimate the risk of appropriate therapy is crucial. Methods: Patients with IC and an ICD for primary prevention implanted between 2006 and 2019 were retrospectively analyzed for appropriate therapy (ATh). The primary objective was to assess predictors of ATh development. The secondary objective was to assess the impact of ATh on survival. Results: Overall, 260 patients (age 67.3 ± 9.4 years, 15.4% female) were analyzed with a follow-up of 4.47 ± 3.02 years. ATh occurred in 79 patients (30.4% of the study group). Independent risk factors for ATh were as follows: non-sustained ventricular tachyarrhythmias (nsVTs) detected before ICD implantation, extensive area of ischemic left ventricular damage on echocardiographic assessment, left ventricular end-diastolic dimension (LVEDd) ≥ 68 mm, history of coronary artery bypass grafting (CABG), and presence of chronic total occlusion (CTO). A multiparameter logit model was created to estimate the probability of ATh. Patients with a score ≥ 0.6 had more than a six-fold higher risk of developing ATh compared with patients with a score < 0.6. Patients after ATh had significantly lower survival compared to patients without intervention (HR 1.69, p = 0.008). Conclusions: Patients with the independent risk factors listed above are at higher risk for ATh. A multiparameter logit model based on these risk factors is effective in estimating the risk of ATh. The occurrence of ATh was associated with a significantly higher risk of all-cause mortality.

15 June 2026 in Medical Science Monitor
Verified
Journal Article
Open access
RWRadosław Wontor
Radosław Wontor
MŁMaria Łoboz-Rudnicka
Maria Łoboz-Rudnicka
BOBogusława Ołpińska
Bogusława Ołpińska
KDKrzysztof Dudek
Krzysztof Dudek
MLMagdalena Lisiak
Magdalena Lisiak
JJJoanna Jaroch
Joanna Jaroch
With an aging population, there is a growing proportion of patients with frailty and acute coronary syndrome (ACS). However, there is a paucity of data on optimal management and risk stratification. We aimed to assess the impact of frailty on early and midterm adverse events in patients with ACS. This was a prospective, observational study including 196 patients aged 65 years or older (mean age 74.4 years) with ACS. Frailty was assessed with the Tilburg Frailty Indicator (TFI). Patients were classified as non-frail (TFI score 0–4), with mild frailty (TFI score 5–8 points), and with moderate/severe frailty (TFI >8 points). In-hospital complications and major cardiovascular and cerebrovascular events (MACCEs) at 6-month follow-up were analyzed. The rate of overall in-hospital complications and prolonged length of stay was increased in frail patients vs non-frail (61.3% vs 25.4%; P<0.001; and 54% vs 16.9%; P<0.001). At 6-month follow-up, MACCEs were observed more often in patients with moderate/severe frailty (22.2% vs 5.1%; P=0.019), and all-cause death more often in patients with frailty vs non-frail (10.9% vs 1.7%; P=0.03). Elevated TFI score was an independent predictor of in-hospital and midterm MACCEs in patients with ACS (TFI ≥5 points for in-hospital, and ≥8 points for midterm complications). Frailty syndrome is associated with impaired early and midterm outcomes in older adult patients with ACS, independent of chronological age. Assessment of frailty in patients with ACS provides data valuable for risk stratification and management.